Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

2019664 citationsJournal Articlebronze Open Access

Authors

Ajai Chari · Tisch Hospital

Dan T. Vogl · Tisch Hospital

Maria Gavriatopoulou · National and Kapodistrian University of Athens

Ajay K. Nooka · Emory University

Andrew J. Yee · Massachusetts General Hospital

Carol Ann Huff · Johns Hopkins University

Philippe Moreau ·

Abstract

Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies. (Funded by Karyopharm Therapeutics; STORM ClinicalTrials.gov number, NCT02336815.).

Topics & Keywords

Multiple Myeloma Research and Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 8, pp. 727-738

DOI: 10.1056/nejmoa1903455

Field-Weighted Citation Impact: 66.66